Axsome Therapeutics (AXSM) Short term Debt (2016 - 2026)

Axsome Therapeutics (AXSM) has 10 years of Short term Debt data on file, last reported at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 29.62% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (up 29.62% YoY), and the FY2025 full-year result was $10.0 million, changed N/A from the prior year.
• Short term Debt advanced to $11.2 million in Q1 2026, from $10.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $11.2 million in Q1 2026 to a low of $5.9 million in Q4 2022.
• A 5-year average of $7.6 million and a median of $7.0 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt declined 4.69% in 2023 and jumped 34.66% in 2025, its largest moves.
• Tracing AXSM's Short term Debt over 5 years: stood at $5.9 million in 2022, then grew by 8.59% to $6.4 million in 2023, then climbed by 26.91% to $8.1 million in 2024, then advanced by 23.13% to $10.0 million in 2025, then advanced by 11.37% to $11.2 million in 2026.
• Business Quant data shows AXSM's Short term Debt at $11.2 million in Q1 2026, $10.0 million in Q4 2025, and $9.7 million in Q3 2025.